| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Annexon Inc. | ANX007 vs SYFOVRE - (ARROW) | Geographic atrophy (GA) | Phase 3 | Trial Planned | ANX007 intravitreal SYFOVRE intravitreal | Opthalmic |
| Annexon Inc. | ANXV | Retinal vein occlusion (RVO) | Phase 2 | Data Released | Intravenous | Opthalmic |
| Annexon Inc. | ANX005 - (wAIHA) | Warm autoimmune hemolytic anemia (WAIHA) | Phase 2 | Trial Discontinued | Intravenous | Hematology |
| Annexon Inc. | Tanruprubart (ANX005) | Guillain-Barré Syndrome (GBS) | BLA Filing | Data Released | Intravenous | Neurology |
| Annexon Inc. | ANX007 - (ARCHER-II) | Geographic atrophy | Phase 2 | Enrollment Conclusion | Intravitreal | Opthalmic |
| Annexon Inc. | ANX005 | Huntington’s disease (HD) | Phase 2/3 | Trial Planned | Intravenous | Neurology |
| Annovis Bio Inc. | Buntanetap (ANVS401) | Alzheimer’s disease (AD) | Phase 3 | Enrollment Initiation | Oral | Neurology |
| Annovis Bio Inc. | Buntanetap | Parkinson's Disease (PD) | Phase 3 | Ongoing | Oral | Neurology |